New drug combo tested for Tough-to-Treat liver cancer
NCT ID NCT06309485
Summary
This study is testing whether adding an experimental drug called WGI-0301 to the standard drug sorafenib can help control advanced liver cancer. It is for adults whose cancer has worsened after trying a previous type of immunotherapy. The main goals are to find the safest dose of the combination and see if it effectively shrinks tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China Pharmaceutical University, Shanghai Gobroad Cancer Hospital
RECRUITINGShanghai, Shanghai Municipality, 200131, China
-
Prince of Wales Hospital
NOT_YET_RECRUITINGHong Kong, Hong Kong
-
Sir Run Run Shaw Hospital Zhejiang University School of Medicine
RECRUITINGHangzhou, China
-
West China Hospital Sichuan University
RECRUITINGChengdu, China
Conditions
Explore the condition pages connected to this study.